Methods for detecting predisposition to cancer at the MTS gene
First Claim
1. A method for diagnosing a polymorphism associated with predisposition for cancer selected from the group consisting of melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin'"'"'s lymphoma, chronic lymphocytic leukemia (CLL), and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum, in a human comprising:
- detecting a germline alteration of a wild-type Multiple Tumor Suppressor gene or its expression products in a human sample wherein said Multiple Tumor Suppressor gene or said expression product is a nucleic acid or a polypeptide defined by any one of the group of SEQ ID NOs;
1-5, 13-16, 24 and 36, said alteration indicating a predisposition to at least one of said cancers.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin'"'"'s lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
96 Citations
34 Claims
-
1. A method for diagnosing a polymorphism associated with predisposition for cancer selected from the group consisting of melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin'"'"'s lymphoma, chronic lymphocytic leukemia (CLL), and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum, in a human comprising:
- detecting a germline alteration of a wild-type Multiple Tumor Suppressor gene or its expression products in a human sample wherein said Multiple Tumor Suppressor gene or said expression product is a nucleic acid or a polypeptide defined by any one of the group of SEQ ID NOs;
1-5, 13-16, 24 and 36, said alteration indicating a predisposition to at least one of said cancers. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
- detecting a germline alteration of a wild-type Multiple Tumor Suppressor gene or its expression products in a human sample wherein said Multiple Tumor Suppressor gene or said expression product is a nucleic acid or a polypeptide defined by any one of the group of SEQ ID NOs;
-
34. A method for confirming the lack of a predisposition for cancer at the Multiple Tumor Suppressor locus in a human, comprising:
- detecting the wild-type Multiple Tumor Suppressor gene or its expression products in a human sample, wherein said Multiple Tumor Suppressor gene or said expression product is a nucleic acid or a polypeptide defined by any one of the group of SEQ ID NOs;
1-5, 13-16, 24 and 36, the presence of the wild-type gene or expression products indicating no predisposition to cancer at the Multiple Tumor Suppressor locus.
- detecting the wild-type Multiple Tumor Suppressor gene or its expression products in a human sample, wherein said Multiple Tumor Suppressor gene or said expression product is a nucleic acid or a polypeptide defined by any one of the group of SEQ ID NOs;
Specification